|
| |
Country
|
| |
Belgium |
United States |
France |
|
| Study authors |
Vermylen et al21 |
Walters et al19,24 |
Current study |
| Period |
04/86–01/97 |
09/91–03/99 |
11/88–12/04 |
| No. of patients |
50 |
50 |
87 |
| Median age, y (range) |
7.7 (0.9–23) |
9.9 (3.3–14) |
8.8 (2.2–22) |
| No. of strokes (%) |
4 (8) |
14/26 (54) |
36 (41) |
| Mean ferritin level, ng/mL (range) |
? |
1542 (58–6795) |
911 (13–3820) |
| ATG source |
Fresenius |
Horse ATGAM |
Rabbit ATG |
| ATG dose |
15–90 mg/kg |
90 mg/kg |
20 mg/kg |
| Follow-up |
|
|
|
| Median, y (range) |
5 (0.9–15) |
3.3 (0.5–7.9) |
6 (2–17.9) |
| More than 2 y |
— |
26 |
87 |
| Rejections, % |
10 |
10 |
7 |
| TRM, % |
7 |
6 |
6.9 |
| EFS, % |
82 |
84 |
86.1 |
| aGvHD above grade II |
20 |
15 |
20 |
| cGvHD |
20 |
12 |
13.5 |
| |